AIMS: To model the biotransformation steps of 5-FU production from capecitabine and identify patient characteristics that may influence the drug disposition. METHODS: Blood samples and demographic data were collected from two phase I studies in which adult patients received oral capecitabine for various malignancies. Capecitabine, 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR) and 5-fluorouracile (5-FU) concentration-time data were analysed via a population approach using NONMEM. RESULTS: Forty patients and 75 pharmacokinetic time-courses were available for analysis. Capecitabine pharmacokinetics was ascribed to a one compartment model from which 5'-DFCR, 5'-DFUR and 5-FU were sequentially produced. Capecitabine oral absorption was characterized by a rapid first order input (K(a)=2.1 +/- 0.3 hr(-1)) with a lag time (0.28 +/- 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable. The capecitabine CL (CL10 = 218+/- 18 L/hr, ISV = 18%) and 5'-DFUR elimination rate constant (K34 = 5.3 +/- 2.0 hr(-1), ISV = 25%) were influenced by total bilirubin (BILT). The elimination rate constant of plasma 5-FU (K40) was 66 +/- 24 hr(-1) (ISV = 34%). The final pharmacokinetic model was validated using 2000 bootstrap runs and provided non-parametric statistics of the parameters (median, 2.5th and 97.5th percentiles). CONCLUSIONS: This study supported the possibility of modelling a complex sequential metabolic pathway which produces pharmacologicaly active compounds from a prodrug. Only BILT significantly influenced the pharmacokinetics but this effect was not considered as relevant for dosing adjustment.
AIMS: To model the biotransformation steps of 5-FU production from capecitabine and identify patient characteristics that may influence the drug disposition. METHODS: Blood samples and demographic data were collected from two phase I studies in which adult patients received oral capecitabine for various malignancies. Capecitabine, 5'-deoxy-5-fluorocytidine (5'-DFCR), 5'-deoxy-5-fluorouridine (5'-DFUR) and 5-fluorouracile (5-FU) concentration-time data were analysed via a population approach using NONMEM. RESULTS: Forty patients and 75 pharmacokinetic time-courses were available for analysis. Capecitabine pharmacokinetics was ascribed to a one compartment model from which 5'-DFCR, 5'-DFUR and 5-FU were sequentially produced. Capecitabine oral absorption was characterized by a rapid first order input (K(a)=2.1 +/- 0.3 hr(-1)) with a lag time (0.28 +/- 0.11 hr), but related inter-occasion (IOV) and inter-subject (ISV) variabilities for these parameters, 167% and 110%, indicated that this oral absorption was highly variable. The capecitabine CL (CL10 = 218+/- 18 L/hr, ISV = 18%) and 5'-DFUR elimination rate constant (K34 = 5.3 +/- 2.0 hr(-1), ISV = 25%) were influenced by total bilirubin (BILT). The elimination rate constant of plasma 5-FU (K40) was 66 +/- 24 hr(-1) (ISV = 34%). The final pharmacokinetic model was validated using 2000 bootstrap runs and provided non-parametric statistics of the parameters (median, 2.5th and 97.5th percentiles). CONCLUSIONS: This study supported the possibility of modelling a complex sequential metabolic pathway which produces pharmacologicaly active compounds from a prodrug. Only BILT significantly influenced the pharmacokinetics but this effect was not considered as relevant for dosing adjustment.
Authors: B Reigner; J Verweij; L Dirix; J Cassidy; C Twelves; D Allman; E Weidekamm; B Roos; L Banken; M Utoh; B Osterwalder Journal: Clin Cancer Res Date: 1998-04 Impact factor: 12.531
Authors: Christopher Poole; Jill Gardiner; Chris Twelves; Patrick Johnston; Peter Harper; Jim Cassidy; Jayne Monkhouse; Ludger Banken; Erhard Weidekamm; Bruno Reigner Journal: Cancer Chemother Pharmacol Date: 2002-01-10 Impact factor: 3.333
Authors: Bruno Reigner; Toru Watanabe; Johannes Schüller; Helen Lucraft; Yasutsuna Sasaki; John Bridgewater; Toshiaki Saeki; James McAleer; Masaru Kuranami; Christopher Poole; Mitsunori Kimura; Jayne Monkhouse; Cahit Yorulmaz; Erhard Weidekamm; Susan Grange Journal: Cancer Chemother Pharmacol Date: 2003-05-29 Impact factor: 3.333
Authors: Ron J Keizer; Miren K Zamacona; Mendel Jansen; David Critchley; Jantien Wanders; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Invest New Drugs Date: 2008-08-20 Impact factor: 3.850
Authors: Z Daher Abdi; S Lavau-Denes; A Prémaud; S Urien; F L Sauvage; J Martin; S Leobon; P Marquet; N Tubiana-Mathieu; A Rousseau Journal: Cancer Chemother Pharmacol Date: 2014-05-07 Impact factor: 3.333
Authors: Bart A W Jacobs; Maarten J Deenen; Markus Joerger; Hilde Rosing; Niels de Vries; Didier Meulendijks; Annemieke Cats; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: CPT Pharmacometrics Syst Pharmacol Date: 2019-11-20
Authors: Laura Molenaar-Kuijsten; Bart Albertus Wilhelmus Jacobs; Sophie Alberdine Kurk; Anne Maria May; Thomas Petrus Catharina Dorlo; Jacob Hendrik Beijnen; Neeltje Steeghs; Alwin Dagmar Redmar Huitema Journal: Cancer Med Date: 2021-06-14 Impact factor: 4.452